Trastuzumab in early-stage breast cancer: the question of treatment timing.
Simoens
Steven
S
Research Centre for Pharmaceutical Care and Pharmacoeconomics, Katholieke Universiteit Leuven, Leuven, Belgium. steven.simoens@pharm.kuleuven.be
D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000191:economics; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000191:economics; D003362:Cost-Benefit Analysis; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D009367:Neoplasm Staging; D013997:Time Factors; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068878:Trastuzumab
Health Policy. 2008 Aug;87(2):146-59
18164510
J Clin Oncol. 2005 Nov 1;23(31):7811-9
16258083
Ann Oncol. 2007 Sep;18(9):1493-9
17761705
N Z Med J. 2007 Jun 15;120(1256):U2593
17589560
Pharmacoeconomics. 2007;25(5):429-42
17488140
Lancet. 2007 Jan 6;369(9555):29-36
17208639
N Engl J Med. 2006 Feb 23;354(8):809-20
16495393
Pharmacoeconomics. 2008;26(8):699-719
18620462
Pharmacoeconomics. 2007;25(3):181-5
17335304
N Engl J Med. 2005 Oct 20;353(16):1659-72
16236737
Lancet. 2008 May 17;371(9625):1644-6
18486727
J Clin Oncol. 2008 Mar 10;26(8):1231-8
18250349